BioXcel Therapeutics Inc BTAI.OQ BTAI.O is expected to show a fall in quarterly revenue when it reports results on March 25 (estimated) for the period ending December 31 2025
The New Haven Connecticut-based company is expected to report a 55.7% decrease in revenue to $162 thousand from $366 thousand a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for BioXcel Therapeutics Inc is for a loss of 75 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -1.17 | -1.18 | -2.18 | Missed | -85.1 |
Jun. 30 2025 | -1.90 | -1.86 | -2.45 | Missed | -32 |
Mar. 31 2025 | -8.45 | -6.66 | -1.50 | Beat | 77.5 |
Dec. 31 2024 | -6.04 | -6.42 | -3.57 | Beat | 44.4 |
Sep. 30 2024 | -8.00 | -8.67 | -5.12 | Beat | 40.9 |
Jun. 30 2024 | -11.12 | -11.36 | -3.36 | Beat | 70.4 |
Mar. 31 2024 | -10.25 | -11.17 | -13.92 | Missed | -24.6 |
Dec. 31 2023 | -15.12 | -14.56 | -12.16 | Beat | 16.5 |
This summary was machine generated March 23 at 12:38 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments